Eli Lilly and Company $LLY Stock: First Command Advisory Services Inc. Decreases Holdings

First Command Advisory Services Inc. decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 29.4% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,550 shares of the company’s stock after selling 645 shares during the quarter. First Command Advisory Services Inc.’s holdings in Eli Lilly and Company were worth $1,793,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LLY. Silver Grove Financial Group Inc. grew its position in Eli Lilly and Company by 2.0% in the third quarter. Silver Grove Financial Group Inc. now owns 1,008 shares of the company’s stock valued at $1,166,000 after acquiring an additional 20 shares during the period. Davis Investment Partners LLC lifted its holdings in shares of Eli Lilly and Company by 2.7% during the third quarter. Davis Investment Partners LLC now owns 1,277 shares of the company’s stock valued at $1,477,000 after acquiring an additional 34 shares during the period. Illinois Municipal Retirement Fund boosted its stake in shares of Eli Lilly and Company by 2.0% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 57,175 shares of the company’s stock valued at $66,156,000 after purchasing an additional 1,130 shares in the last quarter. Northbridge Financial Group LLC boosted its stake in shares of Eli Lilly and Company by 2.1% in the 3rd quarter. Northbridge Financial Group LLC now owns 2,711 shares of the company’s stock valued at $3,138,000 after purchasing an additional 56 shares in the last quarter. Finally, Brooklyn FI LLC acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at $714,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $1,437.46 on Thursday. The stock’s fifty day moving average is $1,231.13 and its 200-day moving average is $1,106.42. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The stock has a market capitalization of $1.35 trillion, a PE ratio of 46.66, a PEG ratio of 1.72 and a beta of 0.40. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,453.00.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm’s quarterly revenue was up 38.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $7.02 EPS. Equities research analysts expect that Eli Lilly and Company will post 35.67 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s payout ratio is currently 22.46%.

Insider Buying and Selling

In related news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Eli Lilly and Company

Investors following LLY have been watching these headlines:

• Positive Sentiment: Foundayo, Lilly’s GLP-1 weight-loss pill, was reported to have shown substantial improvement in sleep apnea, adding to the potential uses of the company’s obesity pipeline. Article: Foundayo and sleep apnea
• Positive Sentiment: A recent report says Lilly raised its 2026 sales outlook to as much as $92 billion, reinforcing expectations that strong demand for its obesity and diabetes medicines can drive continued growth. Article: Lilly’s 2026 sales outlook
• Negative Sentiment: The FDA is requiring GLP-1 drugmakers to add a warning about rare NAION-related vision loss. Zepbound is among the medicines affected, creating a potential safety concern for Lilly’s key product category. Article: FDA warning on GLP-1 drugs

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on LLY shares. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Royal Bank Of Canada boosted their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an “outperform” rating in a research report on Friday, October 30th. Truist Financial reaffirmed a “buy” rating and set a $1,612.00 price objective (up from $1,376.00) on shares of Eli Lilly and Company in a research note on Friday, October 30th. Argus raised their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Finally, Guggenheim raised their price objective on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a report on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,416.64.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.